Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSAstraZeneca's eleglipron, the oral small-molecule GLP-1 agonist licensed from Eccogene in 2023, met primary endpoints in Phase 2b VISTA (310 obesity patients, 26-week weight loss) and SOLSTICE (406 T2D patients, 26-week HbA1c vs semaglutide). Full data at ADA 2026 in June. AstraZeneca commits to a comprehensive Phase 3 program, adding a third serious entrant to the oral GLP-1 race.
Lilly disclosed an ADA 2026 abstract slot for animal data on a unimolecular quintuple agonist engaging GLP-1, GIP, glucagon, amylin, and calcitonin receptors. The compound is distinct from the DiMarchi-Tschöp-Müller GLP-1R/GIPR/PPAR conjugate covered May 1, but the convergence of two independent groups producing five-pharmacophore obesity drugs in the same publication window is a real signal about where multi-agonist development is heading.
Novo's high-dose Wegovy (semaglutide 7.2 mg injection), FDA-approved in March and launched April 7, contributed to the Q1 print on STEP UP trial data showing 21% mean weight loss at 72 weeks and 89% of patients achieving at least 5% body-weight reduction. Dysesthesia at 22% (vs 6% on 2.4 mg and 0.3% placebo) is the safety chapter prescribers will need to engage explicitly. Step-up requires four-plus weeks tolerability on standard dose first.
Eli Lilly disclosed positive topline results from TRANSCEND T2D1 on the April 30 Q1 call. The triple GLP-1/GIP/glucagon agonist lowered A1c by 1.7 to 2.0 percentage points and produced mean weight loss of 25 to 37 pounds versus placebo in adults with type 2 diabetes. Seven more Phase 3 readouts are expected in 2026, with regulatory submission targeted for late 2026 or 2027.
Boehringer and Zealand reported 16.6% mean weight loss at 76 weeks for survodutide in Phase 3 SYNCHRONIZE-1, versus 3.2% on placebo, with predominantly fat-mass loss and 85.1% of treated patients clearing the 5% threshold. The same announcement advanced BI 3034701, a triple GLP-1/GIP/NPY2 agonist, into Phase 2 mid-2026.
Novo Nordisk's PIONEER TEENS Phase 3a trial in 132 kids aged 10 to 17 with type 2 diabetes cut HbA1c by 0.83 percentage points more than placebo at 26 weeks. Filing for label expansion is planned for H2 2026. It would be the first oral GLP-1 receptor agonist in this age group.
Coracle Research published a 50-page defensive disclosure on April 25 covering an oral peptide tablet architecture for seven metabolic peptides, including tirzepatide and retatrutide. Predicted bioavailability runs 2 to 7 times Rybelsus. The publication exists specifically to make the architecture unpatentable.
Orforglipron activates the same GLP-1 receptor as Ozempic without a peptide backbone. Tirzepatide still has the efficacy lead. Here is what the peptide pipeline loses and what it keeps.
Tirzepatide produced 22% weight loss vs 15% for semaglutide in a head-to-head trial. The bigger number wins the weight race but comes with a bigger muscle cost. A third hormone may fix it.
New real-world data suggests tirzepatide loses more muscle than semaglutide at matched weight reduction. The next generation of drugs is adding a glucagon receptor to protect muscle.
Svetlana Mojsov identified the active form of GLP-1 in 1983. Every Ozempic, Wegovy, Mounjaro, and Zepbound traces back to her work. Public credit took forty years to catch up.
Orforglipron is the first pill in the Ozempic class. In a two-year diabetes trial of 2,749 adults, it cut deaths by more than half compared to standard insulin therapy.